Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
DURECT Corporation

DURECT Corporation (DRRX) Stock Overview

Explore DURECT Corporation’s financial performance, market position, analyst ratings, and future outlook.

DRRX●NASDAQ
HealthcareDrug Manufacturers - Specialty & Generic
$1.91
$0.02(1.04%)
U.S. Market is Open · 13:56

DURECT Corporation (DRRX)

Meyka AI Score

Z

Key Financials

Market Cap59.3M
P/E Ratio-9.41
EPS (TTM)$-0.43
ROE-1.40%
Fundamental Analysis

AI Price Forecasts

1 MonthN/A
3 MonthsN/A
1 Year Target$0.00

DRRX Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of DURECT Corporation (NASDAQ: DRRX) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of C+, DURECT Corporation's NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of DRRX on the NASDAQ shows an RSI of N/A, suggesting the stock is in a an undetermined condition. Our forecasting models predict a 12-month price target of $0.00 for the NASDAQ listing.

Key metrics behind DURECT Corporation's NASDAQ-traded stock include a P/E ratio of -9.41 and a market capitalization of 59.3M. Combined with our AI analysis, these give both institutional and retail investors a clear view of DRRX on the NASDAQ.

Price Performance (NASDAQ: DRRX)

1-Day Change
N/A
5-Day Change
N/A
1-Month Change
N/A
3-Month Change
205.26%
6-Month Change
155.007%
Year-to-Date (YTD) Change
141.53%
1-Year Change
46.92%
3-Year Change
-63.27%
5-Year Change
-90.26%
All-Time (Max) Change
-98.67%

Contact Information

https://www.bauschhealth.com
408 777 1417
10260 Bubb Road, Cupertino, CA, 95014-4166

Company Facts

210 Employees
IPO DateSep 28, 2000
CountryUS

Frequently Asked Questions